Immunocore Holdings plc (IMCR) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $27.79: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 10.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum.
Immunocore is a commercial-stage biotech with KIMMTRAK (tebentafusp) approved in 39 countries for HLA-A*02:01-positive metastatic uveal melanoma, generating $400M in 2025 net therapy revenue. US accounts for the majority of revenue ($257M); additional pipeline programs target... Read more
Sell if holding. Engine safety override at $27.79: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 10.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.8/10, moderate confidence.
Passes 7/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 59d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Immunocore Holdings plc
Latest news
- NEWS H.C. Wainwright reiterates Immunocore stock rating citing KIMMTRAK penetration By Investing.com - Investing.com South Af — Investing.com South Africa positive
- NEWS IMCR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus — GuruFocus positive
- NEWS HC Wainwright Reiterates "Buy" Rating for Immunocore (NASDAQ:IMCR) - MarketBeat — MarketBeat positive
- NEWS Immunocore (IMCR): Clinical Momentum, Credible Management, and Industry Visibility Support Buy Rating - TipRanks — TipRanks positive
- NEWS Immunocore (IMCR) upgraded to strong buy: Here's why - MSN — MSN positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Unprofitable operations — net margin -6.7%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $27.79: Quality below floor (3.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.8/10 and A.R:R 10.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 20%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $26.82. Score 5.8/10, moderate confidence.
Take-profit target: $55.24 (+98.8% upside). Prior stop was $26.82. Stop-loss: $26.82.
Quality below floor (3.0 < 4.0).
Immunocore Holdings plc trades at a P/E of N/A (forward -41.4). TrendMatrix value score: 8.6/10. Verdict: Sell.
23 analysts cover IMCR with a consensus score of 4.1/5. Average price target: $63.
What does Immunocore Holdings plc do?Immunocore is a commercial-stage biotech with KIMMTRAK (tebentafusp) approved in 39 countries for HLA-A*02:01-positive...
Immunocore is a commercial-stage biotech with KIMMTRAK (tebentafusp) approved in 39 countries for HLA-A*02:01-positive metastatic uveal melanoma, generating $400M in 2025 net therapy revenue. US accounts for the majority of revenue ($257M); additional pipeline programs target cutaneous melanoma, ovarian cancer, NSCLC, HIV, and autoimmune disease using the ImmTAX bispecific platform. Manufacturing is fully outsourced to CMOs AGC Biologics and Simtra Biopharma.